Genetic risk of inflammatory bowel disease is associated with disease course severity

Authors: Marie Vibeke Vestergaard[1]*, Kristine Højgaard Allin[1,2]*, Anne Krogh Nøhr[1]*, Jesus Vicente Torresano Lominchar[1], Heidi Søgaard Christensen[1], Henrik Krarup[3], Kaspar René Nielsen[4], Henrik Albæk Jacobsen[1,2], Jonas Bybjerg-Grauholm[5], Marie Bækvad-Hansen[5], Rasmus Froberg Brøndum[1], Martin Bøgsted[1], Lone Larsen[1,2#], Aleksejs Sazonovs[1#], Tine Jess[1,2#]

[1]Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark

[2]Department of Gastroenterology & Hepatology, Aalborg University Hospital, Aalborg, Denmark

[3]Department of Molecular Diagnostics, Aalborg University Hospital, and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

[4]Department of Clinical Immunology, Zealand University Hospital, Næstved, Denmark

[5]Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institute, Copenhagen, Denmark

*, [#] Contributed equally

Abstract

Background and aims

Genetic susceptibility to inflammatory bowel disease (IBD) has been widely studied, whereas the genetic contribution to disease progression over time remains relatively under-investigated. In a Danish nationwide cohort, we aimed to explore if genetic susceptibility to IBD is associated with disease severity.

Methods

We estimated polygenic scores (PGS) for IBD susceptibility for 3,732 patients with Crohn's disease (CD), 4,535 patients with ulcerative colitis (UC), and 9,469 controls, and investigated their association with disease outcomes, including inflammatory markers, hospitalizations, major surgeries, and medication use. A composite severity outcome was defined based on the first three years following diagnosis. Lastly, we evaluated disease extent as a possible mediator of the association.

Results

Increased susceptibility PGS was associated with higher fecal calprotectin and C-reactive protein levels, and decreased hemoglobin levels. When comparing the highest versus lowest PGS quintile, we observed a hazard ratio (HR) for major surgery of 2.74 (P=7.19×10^{-18}) in patients with CD and of 2.04 (P=4.36×10^{-7}) in UC. Patients with severe disease had higher susceptibility PGS than patients with less severe disease (CD: OR=1.25, P=3.36×10^{-9}; UC: OR=1.33, P=1.40×10^{-15} per SD increase in PGS). Additionally, PGS was associated with a higher need for corticosteroids, immunomodulators, and biologic therapies. Adjusting for disease extent reduced the estimated associations for CD but had little impact on observed associations for UC.

Conclusion

Patients with higher genetic burden for developing IBD also experience a more severe disease course. For patients with CD this link was largely mediated by disease extent, however, this was not the case for UC, which suggests a shared genetic architecture between disease susceptibility and severity.

Keywords

Inflammatory bowel disease, polygenic scores, disease course severity; population-wide

Introduction

Inflammatory bowel disease (IBD) is a chronic, progressive, immune-mediated intestinal disease with an increasing incidence and prevalence globally. The two most common subtypes of the disease are Crohn's disease (CD) and ulcerative colitis (UC).[1,2] Patients are often diagnosed in early adulthood and experience a serious, life-altering condition that does not currently have curative treatment. The disease course is highly heterogeneous, ranging from relatively mild symptoms to severe disease characterized by uncontrolled gastrointestinal inflammation and repeated hospitalizations and surgeries.[3,4] A better understanding of which patients will experience a more severe disease course would be the first step to improve treatment of this subgroup. However, our current limited understanding of IBD and the factors driving its heterogenicity make it difficult to anticipate a patient's disease course.

Genome-wide association studies (GWAS) of IBD have primarily focused on disease onset by comparing patients with IBD to population controls. To date, more than 400 susceptibility loci have been identified.[5,6] However, research on the genetic contribution to disease progression is more limited. In an analysis of approximately 2700 patients with CD performed by Lee *et al.*,[7] four individual loci were associated with the need for immunomodulators or gastrointestinal surgeries. These loci were not associated with disease susceptibility.

Polygenic scores (PGS) use the results from GWAS to calculate the aggregated effect of trait-associated variants carried by an individual. To date, PGS has primarily been used to model the individual risk of disease onset for complex diseases where a well-powered, large-scale GWAS exists. For IBD, PGS can predict disease onset with limited performance (area under the receiver operating characteristic curve (AUC) = 0.63) and only identifies ~3.2% of the population with a threefold increased risk of IBD.[8] As for genetics overall, very little is known about the impact of genetics on the course of IBD. Although a strong association between PGS and disease extent has been reported,[9] previous studies have failed to identify an association between susceptibility PGS and anti-TNF response,[10] and CD prognosis stratified by disease extent.[7]

In this study, we used a large, unique population-based IBD cohort with both genetics and long-term clinical data to investigate the hypothesis that an individual's genetic burden, as measured by their IBD susceptibility PGS, impacts the severity of the disease course.

Methods and materials

Danish registries

The study was based on data from Danish registries, including the Danish Civil Registration System,[11] The Danish National Patient Registry (DNPR),[12] The Danish National Prescription Registry,[13] The Danish nationwide Registry of Laboratory Results for Research (RLRR)[14] and the Danish Pathology Registry (DPR)[15]. Combined, they hold information on inpatient hospital contacts, International Classification of Diseases 8th and 10th revision (ICD-8 and -10) codes, surgical and other procedures since 1977, outpatient contacts since 1995, redeemed prescriptions for Danish residents at all pharmacies since 1994, results of biochemistry and hematological tests from hospitals and general practitioners since 2008 with complete coverage from 2015, and diagnostic statements from pathology departments since 1997. We had data available until September 2022. All registry codes used are listed in Table S1.

Source populations

The PREDICT neonatal blood spot cohort (PREDICT-NBS cohort). The Danish National Biobank stores neonatal blood spots from almost all Danes born since 1982.[16] The PREDICT-NBS cohort includes neonatal blood spots from individuals born and diagnosed with IBD between April 1981 and December 2018. Identification of patients with IBD was based on previously described criteria.[2] IBD patients should have at least two IBD-related hospital registrations within a two-year period, or two separate inpatient contacts recorded in the DNPR. Assignment of CD or UC was based on the two most recent hospital contacts if these were concordant, and otherwise according to the highest number of diagnoses. Date of diagnosis was the date of the first IBD-related hospital registration. Patients not living in Denmark during the two years before this first IBD-related hospital registration were excluded to ensure a valid date of diagnosis. Each IBD patient was matched 1:1 to controls based on sex, date of birth, and no diagnosis of IBD prior to the patient's diagnosis date. Matched controls that developed IBD from end of cohort selection (December 2018) to end of available registry data (September 2022) were considered IBD patients.

The North Denmark IBD cohort (NorDIBD). The NorDIBD cohort is a population-based cohort of all patients from the North Denmark Region with a confirmed IBD diagnosis from 1978 to 2020.[17] From this cohort, 940 patients with IBD and a further 973 blood donors with no IBD diagnosis were genotyped from whole blood. The date of IBD diagnosis was based on patient health records.

Overlapping individuals between the two cohorts (n=233) were randomly excluded from one of the cohorts, and only individuals of European ancestry were included. Details on genotyping, quality control, and

100 generation of genetic principal components (PCs) were previously described[18] and available in Supplement
101 1 and summarized in Figure S1.

102 **Polygenic score**

103 We downloaded and applied variant loadings for calculating PGS for CD and UC susceptibility generated by
104 Middha *et al.*[19], to our dataset. These variant loadings were derived from summary statistics from the
105 IIBDGC[20] and calibrated on UK Biobank data. We calculated PGS using Plink; 738,417 out of 744,682 (>99%)
106 and 738,314 out of 744,575 (>99%) available variants were included for calculating CD and UC susceptibility
107 PGS, respectively. We also calculated CD and UC susceptibility PGS for the controls. The mean (SD) of CD
108 PGS across controls and CD patients was 1.00 (1.27) and the corresponding mean (SD) of UC PGS across
109 controls and UC patients was -0.95 (1.01). The PGS scores were normalized to standard deviations (SDs)
110 from the mean to improve interpretability.

111 **Outcomes**

112 We examined the association between susceptibility PGS and markers of inflammation i.e., C-reactive
113 protein (CRP), fecal calprotectin (f-calpro) and hemoglobin at time of diagnosis and during follow-up. At
114 diagnosis was defined as ± six months from the date of diagnosis, and the post-diagnosis phase was divided
115 into five one-year intervals from half a year after diagnosis ((0.5,1.5), [1.5, 2.5), [2.5,3.5), [3.5,4.5), and
116 [4.5,5.5) years).

117 Our primary outcomes were time to IBD-related hospitalization exceeding two days and time to major IBD-
118 related surgery. We excluded patients diagnosed before January 1, 1996, to ensure completeness of
119 relevant registries. This resulted in a final study population of 3732 patients with CD (3354 from the
120 PREDICT-NBS cohort and 378 from the NorDIBD cohort), and 4535 patients with UC (4173 from the
121 PREDICT-NBS cohort and 362 from the NorDIBD cohort) (Figure S2).

122 For our secondary outcome we excluded patients with less than three years of follow-up (CD=44, UC=44) to
123 enable the classification of patients as having a severe versus less severe disease course based on the first
124 three years following diagnosis. For patients with CD, we defined a severe disease course as experiencing I)
125 two or more IBD-related hospitalizations exceeding two days, II) two or more IBD-related major surgeries,
126 III) one IBD-related hospitalization and one IBD-related major surgery not overlapping in time, or IV) a total
127 use of at least 5000 mg prednisolone equivalent systemic corticosteroids within the first three years
128 following diagnosis (Figure S3). For patients with UC the severity definition was modified to experiencing I)
129 two or more IBD-related hospitalizations exceeding two days, II) one or more IBD-related major surgeries, or

130 III) a total use of at least 5000 mg prednisolone equivalent systemic corticosteroids. Patients not fulfilling
131 these criteria were considered less severe.

132 We further tested each entity of the composite severity outcome separately: two or more IBD-related
133 hospitalizations exceeding two days, two or more IBD-related major surgeries, one or more IBD-related
134 major surgeries, and a total use of at least 5000 mg systemic corticosteroids within the first three years
135 following diagnosis. Additionally, we evaluated the association with treatment with biologics, and
136 immunomodulators for patients diagnosed after January 1, 2003, and the cumulative use of different
137 treatment options within the first three years.

138 Definitions and codes used are listed in Table S1.

139 **Statistical analyses**

140 At- and post-diagnosis biochemistry test values of CRP, f-calpro, and hemoglobin were evaluated for
141 association with susceptibility PGS using a linear regression model adjusting for the covariates sex, cohort,
142 calendar year, age at diagnosis, and the first ten PCs. This was only done for individuals with available
143 measurements. Where there were multiple samples per individual in the same interval, the sample closest
144 to date of diagnosis was chosen for the at-diagnosis interval, whereas the median value was chosen for the
145 post-diagnosis intervals. Test values were transformed using log transformation for CRP and f-calpro to
146 approach a Gaussian distribution.

147 We analyzed the association between susceptibility PGS and time to first IBD-related hospitalization
148 exceeding two days and first major IBD-related surgery using Cox proportional hazards regression models.
149 Censoring was based on death, emigration, or end of study. The model included adjustments for the above-
150 mentioned covariates. Cumulative incidence curves were generated to visualize the association by dividing
151 patients into PGS quintiles.

152 We analyzed the association between susceptibility PGS and our primary and secondary binary outcomes
153 using logistic regression, adjusting for the above-mentioned covariates.

154 Reported p-values from tests of secondary outcomes and from biochemistry test values were adjusted for
155 multiple testing using the Bonferroni correction. All results are reported per SD increase of susceptibility
156 PGS.

157 **Sensitivity analyses**

158 Sensitivity analyses were generated to evaluate the disease extent as a mediator of the association between
159 susceptibility PGS and disease course severity.

160 We repeated the statistical analyses after recalculating the PGS by excluding the genetic loci MST1, NOD2,
161 ATG16L1, and the HLA region ±500 kb, as these genetic regions are known to associate with disease
162 extent.[9,21]

163 As a final sensitivity analysis, we inferred disease extent by using information from the DPR for the subset of
164 patients with available data[22]. Ileal CD (L1) was inferred if patients had pathology registrations in ileum but
165 not colon, colonic CD (L2) if there were registrations in the colon but not ileum, and ileocolonic CD (L3) for
166 registrations in both the ileum and colon. Upper disease CD (L4) was coded as a separate parameter based
167 on registrations in the upper gastrointestinal tract. Ulcerative proctitis (E1) was inferred if patients had
168 registrations in the rectum but not colon, left-sided colitis (E2) if there were registrations in the descending
169 colon to the sigmoid colon, and extensive colitis (E3) if there were registrations in the cecum to the
170 transverse colon. Data was extracted from 30 days before to three years after diagnosis. If there were
171 multiple records, the most widespread disease extent was selected. Selecting patients with inferred disease
172 extent limited the cohort to 1970 patients with CD and 3067 patients with UC. Disease extent was included
173 as a covariate when repeating the analyses.

174 **Ethical approval**

175 The PREDICT-NBS cohort was approved by the Research Ethical Committee of the Capital Region of
176 Denmark (H-20048987) and no direct consent was required. Collecting and analyzing blood samples from
177 the NorDIBD cohort were approved by the Research Ethical Committee of the North Denmark Region (N-
178 20170005-N-20200071). Oral and written consents were obtained, and we followed up on whether any
179 participant withdrew their consent.

Results

We included 8,267 patients with IBD (3,732 (45%) patients with CD and 4,535 (55%) with UC) and 9,469 control individuals (Table 1). Among patients with CD, the mean age at diagnosis was 21.8 years (SD=7.7), and 56% were female. Among patients with UC, the mean age at diagnosis was 23.3 years (SD=8.4), and 53% were female. Control individuals had a mean normalized PGS of -0.221 for CD PGS and -0.235 for UC PGS. Patients with CD had a mean normalized CD PGS of 0.528, whereas patients with UC had a mean normalized UC PGS of 0.469.

Biochemistry profile is affected by susceptibility genetics

Increased susceptibility PGS was associated with disease activity markers of gastrointestinal and systemic inflammation (Figure 1). At diagnosis, f-calpro was increased (CD: β=0.27, 95% CI=0.21-0.34 log(mg/kg) per SD increase, UC: β=0.21, 95% CI=0.13-0.28 log(mg/kg) per SD increase) and hemoglobin decreased (CD: β=-0.11, 95% CI=-0.15--0.07 mmol/L per SD increase, UC: β=-0.08, 95% CI=-0.13--0.04 mmol/L per SD increase) with higher PGS, whereas CRP was only increased with higher PGS for patients with CD (β=0.15, 95% CI=0.09-0.21 log(mg/L) per SD increase). For patients with CD, increased f-calpro levels remained significantly associated with higher PGS during the following disease course. Thus, we decided to further investigate the association between susceptibility genetics and disease course outcomes of patients.

Higher genetic burden of IBD susceptibility is associated with severe outcomes

We separated the CD and UC cohorts into quintiles based on susceptibility PGS. Looking into the time to first IBD-related hospitalization exceeding two days and time to major IBD-related surgery revealed cumulative incidence curves ranking based on their PGS quintile, where the quintile with lowest PGS had the longest event-free time (Figure 2). This pattern was consistent for both time to hospitalization and time to major surgery for both CD and UC. Comparing the highest PGS quintile to the lowest revealed a quicker time to hospitalization (CD: hazard ratio [HR]=1.81, 95% confidence interval [CI]=1.57-2.09, UC: HR=1.69, 95% CI=1.47-1.95) and to major surgery (CD: HR=2.74, 95% CI=2.18-3.45, UC: HR=2.04, 95% CI=1.55-2.69).

We generated a binary classification of severe and less severe disease courses based on the first three years after diagnosis, as time to the first event does not necessarily reflect the actual severity. We thus subset the CD and UC cohort to patients with at least three years of follow-up after diagnosis (CD=3688, UC=4491) and generated a composite outcome involving number of IBD-related hospitalizations exceeding two days, IBD-related major surgeries and treatment courses with systemic corticosteroids. 1164 patients with CD (31.6%) were classified as having a severe disease course. Correspondingly, 1224 patients with UC (27.3%) were classified as having a severe disease course.

211 The PGS of IBD susceptibility was significantly associated with severe versus less severe disease for both CD
212 and UC (Figure 3A-B). Patients with severe CD had higher PGS than the remaining patients with CD (odds
213 ratio [OR]=1.25, 95% CI =1.16-1.35 per SD increase). Accordingly, 39.2% of CD patients in the highest PGS
214 quintile experienced a severe disease course compared to 23.6% of CD patients in the lowest PGS quintile.
215 This was also the case for patients with UC (OR =1.33, 95% CI=1.24-1.43 per SD increase), where 34.9% of
216 patients in the highest PGS quintile experienced a severe disease course compared to 20.8% in the lowest
217 PGS quintile.

218 We investigated the association between susceptibility PGS and the secondary severity outcomes within the
219 follow-up period: two or more IBD-related hospitalizations exceeding two days, two or more IBD-related
220 major surgeries, one or more IBD-related major surgeries, and a total use of at least 5000 mg systemic
221 corticosteroids (Figure 3C). In general, we observed that all individual components of the main outcome
222 were associated with susceptibility PGS with a consistent effect size ranging from 1.23-1.49 and with
223 overlapping CIs.

224 **Susceptibility PGS is associated with treatment patterns**

225 We further investigated the association between susceptibility PGS and treatment patterns (Figure 4). For
226 this, we focused the analysis on patients diagnosed since 2003 and with three years of follow-up (CD=3353,
227 UC=4149). For both patients with CD and UC we observed significantly increased use of both biologics (CD:
228 OR=1.35, 95% CI=1.25-1.45, UC: OR=1.31, 95% CI=1.21-1.42 per SD increase) and immunomodulators (CD:
229 OR=1.47, 95% CI=1.36-1.58, UC: OR=1.29, 95% CI=1.20-1.38 per SD increase) within the first three years
230 following diagnosis. We further observed a higher proportion of patients administered several types of
231 biologic therapy and immunomodulator with higher PGS quintile, as well as having multiple treatments with
232 systemic corticosteroids.

233 **Disease extent as a mediator of CD severity**

234 We hypothesized that disease extent could be mediating the observed association between susceptibility
235 PGS and the severity of the disease course in CD and UC. Thus, we conducted sensitivity analyses based on
236 a susceptibility PGS calculated excluding the MST1, NOD2, ATG16L1, and HLA regions, known to associate
237 with disease extent in IBD.[9,21] The estimated HR comparing time to IBD-related hospitalization exceeding
238 two days for highest versus lowest PGS quintile was thus 1.54 (95% CI=1.33-1.78) for patients with CD, and
239 1.77 (95% CI=1.54-2.05) for patients with UC (Figure S4). Equivalent results for time to major IBD-related
240 surgery were HR=2.32 (95%CI=1.86-2.91) for patients with CD and HR=1.74 (95% CI=1.32-2.29) for patients

241 with UC. Binary analyses likewise reduced the estimated effect sizes, however the associations remained
242 statistically significant (Figure S5-S6).

243 Lastly, for the patients with available pathology registrations in the interval from 60 days before diagnosis
244 until three years after (CD=1970, UC=3067), we inferred disease extent. Including disease extent as
245 covariates in the statistical analyses reduced the estimated association, especially for CD (Figure 5). Time to
246 IBD-related hospitalization exceeding two days and to major IBD-related surgery, as well as the OR of
247 experiencing at least one major IBD-related surgery and requiring treatment with biologic therapies
248 remained statistically significant in patients with CD after taking disease extent into account. In patients
249 with UC, all outcomes remained statistically associated with susceptibility PGS after adjusting for disease
250 extent.

Discussion

In this population-wide study of more than 8000 patients with IBD with available GWAS data and long-term follow-up, we investigated the influence of IBD susceptibility genetics on the course of IBD using known susceptibility PGS for IBD and a range of longitudinal severity outcomes, including hospitalizations, major surgeries, medication use, and results from biochemistry laboratory tests. We found an association between the aggregated genetic susceptibility to CD and UC and disease severity, however, the association differed between CD and UC, as it appeared to be mainly driven by disease extent in CD, whereas no such pattern was observed in UC.

Using longitudinal nationwide data from biochemistry laboratory tests, we showed that the IBD susceptibility PGS associated with more gastrointestinal inflammation in the form of higher values of f-calpro at time of diagnosis of both CD and UC and during follow-up in patients with CD. Furthermore, susceptibility PGS associated with lower hemoglobin at diagnosis of CD and UC, and elevated CRP in CD but not in UC.

When splitting time to hospitalization exceeding two days and major surgery by PGS quintiles, we observed an additive pattern for both CD and UC, where a higher genetic susceptibility to CD and UC associated with a proportionally higher hazard of hospitalization and major surgery.

In patients with CD, the susceptibility PGS associated most strongly with undergoing major surgery and needing treatment with biologic therapies or immunomodulators. In patients with UC, the susceptibility PGS associated strongly with major surgery and multiple hospitalization events, as well as with a need of treatment with systemic corticosteroids, immunomodulators, and biologic therapies.

Three important susceptibility genes (MST1, NOD2, ATG16L1 and HLA) have been identified to associate with disease extent.[9] Recalculating the PGS without these regions highly reduced the estimated associations with disease course outcomes for patients with CD. Thus, it is possible that the link between susceptibility genetics and disease course severity is mediated by disease extent. It was however not the case for patients with UC, where associations between susceptibility PGS and disease severity were mainly unaltered by adjustment for disease extent. Cleynen *et al.*[9] showed that excluding the three genetic loci from the PGS generation was not sufficient to remove the association with IBD phenotypes. Thus, on the subset of patients with available pathology, we inferred disease extent and included those as covariates in sensitivity analyses. For patients with CD, the adjustment for disease extent highly reduced the estimated association between susceptibility PGS and disease outcomes, which is much in line with the previous findings from Lee et al.[7] It should, however, be noted that selecting patients with available pathology registrations increased

282 the proportion of patients with severe CD from 31.6% to 42.8%, which may introduce selection bias and
283 explain the diminished association. Also, some outcomes remained statistically significant in CD, including
284 those for major surgeries and exposure to biologic therapies and immunomodulators, after adjusting for
285 extent. Notably, and hitherto unstudied at the population-level, an increased risk of UC associated with an
286 increased risk of experiencing a severe disease course independent of the genetic susceptibility of disease
287 extent. This is much in line with our previous findings, that the susceptibility allele HLA-DRB1*01:03 also
288 greatly associated with severity in UC.[18]

289 Complementing the findings from Lee *et al.*[7] and Cleynen *et al.*,[9] our results suggest that IBD susceptibility
290 genetics only explain part of the severity of IBD, hence leaving room for other factors at play. These should
291 be investigated together with genetics and included in future prognostic prediction models. This
292 observation is promising, as it points towards the possibility of modulating the effects of genetic
293 susceptibility through lifestyle interventions directed towards potential environmental factors that are yet
294 to be uncovered. Future prediction models of IBD severity may include the gut microbiota profile[23,24] and
295 biochemistry[25] in addition to genetics. The present study is hopefully a step towards the development of
296 algorithms based on genetics, environmental exposures, and molecular pathways which in the future can
297 identify patients in need of increased monitoring and intensified treatment to prevent disease from
298 progressing and improving their quality of life.

299 The primary strength of this study is its nationwide character and unselected nature, which assures
300 generalizability of findings, as well as the complete longitudinal follow-up of patients. Identifying IBD
301 patients using the Danish registries has previously been validated with a positive predictive value of 95%[26]
302 and completeness of 75-94%.[26,27] A further strength is the use of unique population-based samples for
303 genetic analyses, which was combined with lifetime health data.

304 Our study also has potential limitations, which need to be considered. The cohort is rather young, and our
305 results may primarily reflect the course of IBD in this part of the patient population. Also, inferring disease
306 extent from the national registries are at risk of introducing bias in cohort selection, as mentioned
307 previously, and as the prediction of disease extent has an estimated positive predictive value ranging from
308 0.65 to 0.85 depending on the disease extent category[22]. Laboratory analyses were not available for all
309 patients and their availability may potentially reflect severity. However, to our knowledge no study has been
310 able to test all these parameters over time in a cohort where genetics were also available.

311

312

Conclusion

This study presents novel evidence of an association between the genetic susceptibility burden and subsequent severity of IBD over time, which differs between CD and UC. Patients with higher susceptibility PGS have increased f-calpro and CRP levels, and decreased hemoglobin levels. They experience more hospitalizations, major surgeries and medical treatments, suggesting that genetics of disease susceptibility and disease severity are not orthogonal. However, for patients with CD these associations were greatly mediated by disease extent which was not observed for UC. Our findings of a dose-response relationship between the genetic burden of IBD susceptibility and disease severity provide a new biological understanding of disease severity.

Acknowledgements

We thank the nurses at the outpatient clinic at the Department of Gastroenterology and Hepatology at Aalborg University Hospital, Denmark, for their important contribution to the sample collection. We thank Prof. James C Lee for helpful discussions on result interpretations and validity.

Conflict of Interest

TJ reports consultancy for Ferring and Pfizer. LL reports speaker and consultancy fee from Takeda and Eli Lilly advisory board for Tillotts, Eli Lilly, Abbvie, and Celltrion. HAJ reports speaker fee for Tillotts. The remaining authors have no disclosures.

Author contributions

Conceptualization: MVV, KHA, AKN, MB, AS, TJ

Methodology: MVV, KHA, AKN, HSC, RFB, MB, AS, TJ

Software: MVV, JVTL, AKN, AS

Formal Analysis: MVV, AKN, JVTL, HSG, AS

Investigation (GWAS analysis): MBH, JBG

Resources: LL, HK, KRN, TJ

Data Curation: JVTL, AKN, MVV

Writing – Original Draft: MVV, KHA

Writing – Reviewing & Editing: All authors

Visualization: MVV

Supervision: AS, KHA, TJ

Project Administration: TJ

Funding Acquisition: LL, AS, TJ

Funding

Danish National Research Foundation, DNRF148, Lundbeck Foundation, R313-2019-857, Novo Nordisk Foundation, NNF23OC0087616, The Colitis-Crohn Foreningen.

Data and code availability

This work uses data from the Danish National Health registries (https://sundhedsdatastyrelsen.dk), which is protected by the Danish Act on Processing of Personal Data. To access the data an application is required, which must be approved from the Danish Data Protection Agency and the Danish Health Data Authority.

Code will be made available: https://github.com/marievibeke/PGS_severity

References

1. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017;390:2769–2778.

2. Agrawal M, Christensen HS, Bøgsted M, et al. The Rising Burden of Inflammatory Bowel Disease in Denmark Over Two Decades: A Nationwide Cohort Study. Gastroenterology 2022;163:1547-1554.e5.

3. Torres J, Mehandru S, Colombel JF, et al. Crohn's disease. The Lancet 2017;389:1741–1755.

4. Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. The Lancet 2017;389:1756–1770.

5. Liu Z, Liu R, Gao H, et al. Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries. Nat Genet 2023;55:796–806.

6. Fachal L, Consortium on behalf of the IIG. OP08 Multi-ancestry genome-wide association study of inflammatory bowel disease identifies 125 novel loci and directly implicates new genes in disease susceptibility. J Crohns Colitis 2024;18:i14–i15. Available at: https://dx.doi.org/10.1093/ecco-jcc/jjad212.0008 [Accessed October 28, 2024].

7. Lee JC, Biasci D, Roberts R, et al. Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease. Nature Genetics 2017 49:2 2017;49:262–268. Available at: https://www.nature.com/articles/ng.3755 [Accessed January 7, 2022].

8. Khera A V., Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 2018;50:1219.

9. Cleynen I, Boucher G, Jostins L, et al. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: A genetic association study. The Lancet 2016;387:156–167. Available at: http://www.thelancet.com/article/S0140673615004651/fulltext [Accessed October 23, 2024].

10. Karmi N, Bangma A, Spekhorst LM, et al. Polygenetic risk scores do not add predictive power to clinical models for response to anti-TNFα therapy in inflammatory bowel disease. PLoS One 2021;16.

11. Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 2014;29:541–549.

12. Schmidt M, Schmidt SAJ, Sandegaard JL, et al. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 2015;7:449.

382 13. Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, et al. Data Resource Profile: The Danish National
383 Prescription Registry. Int J Epidemiol 2017;46:798–798f.

384 14. Arendt JFH, Hansen AT, Ladefoged SA, et al. Existing Data Sources in Clinical Epidemiology:
385 Laboratory Information System Databases in Denmark. Clin Epidemiol 2020;12:469–475.

386 15. Bjerregaard B, Larsen OB. The Danish Pathology Register. Scand J Public Health 2011;39:72–74.
387 Available at: https://journals.sagepub.com/doi/10.1177/1403494810393563 [Accessed April 3,
388 2025].

389 16. Nørgaard-Pedersen B, Hougaard DM. Storage policies and use of the Danish Newborn Screening
390 Biobank. J Inherit Metab Dis 2007;30:530–536.

391 17. Larsen L, Karachalia Sandri A, Fallingborg J, et al. Has the Incidence of Inflammatory Bowel Disease
392 Peaked? Evidence From the Population-Based NorDIBD Cohort 1978-2020. Am J Gastroenterol
393 2023;118:501–510.

394 18. Vestergaard MV, Nøhr AK, Allin KH, et al. HLA-DRB1*01:03 and Severe Ulcerative Colitis. JAMA 2024.
395 Available at: https://jamanetwork.com/journals/jama/fullarticle/2825074 [Accessed October 23,
396 2024].

397 19. Middha P, Thummalapalli R, Betti MJ, et al. Polygenic risk score for ulcerative colitis predicts immune
398 checkpoint inhibitor-mediated colitis. Nature Communications 2024 15:1 2024;15:1–10.

399 20. Lange KM De, Moutsianas L, Lee JC, et al. Genome-wide association study implicates immune
400 activation of multiple integrin genes in inflammatory bowel disease. Nat Genet 2017;49:256.

401 21. Kee BP, Ng JG, Ng CC, et al. Genetic polymorphisms of ATG16L1 and IRGM genes in Malaysian
402 patients with Crohn's disease. J Dig Dis 2020;21:29–37. Available at:
403 https://pubmed.ncbi.nlm.nih.gov/31654602/ [Accessed April 25, 2025].

404 22. Bonfils L, Dalsgaard L, Poulsen G, et al. *Validation of date of diagnosis and disease location of*
405 *inflammatory bowel disease in the Danish National Patient Registry and the Danish Pathology*
406 *Registry using a regional cohort*.

407 23. Buffet-Bataillon S, Bouguen G, Fleury F, et al. Gut microbiota analysis for prediction of clinical relapse
408 in Crohn's disease. Scientific Reports 2022 12:1 2022;12:1–8.

24. Hyll Hansen S, Gjerstad Maseng M, Grännö O, et al. Fecal Microbiome Reflects Disease State and Prognosis in Inflammatory Bowel Disease in an Adult Population-Based Inception Cohort. Inflamm Bowel Dis 2025:1–15. Available at: https://dx.doi.org/10.1093/ibd/izaf060 [Accessed April 28, 2025].

25. Vestergaard MV, Allin KH, Poulsen GJ, et al. Characterizing the pre-clinical phase of inflammatory bowel disease. Cell Rep Med 2023;4:101263.

26. Jacobsen HA, Jess T, Larsen L. Validity of Inflammatory Bowel Disease Diagnoses in the Danish National Patient Registry: A Population-Based Study from the North Denmark Region. Clin Epidemiol 2022;14:1099–1109.

27. Fonager K, Toft Sørensen H, Nørby Rasmussen S, et al. Assessment of the diagnoses of Crohn's disease and ulcerative colitis in a Danish hospital information system. Scand J Gastroenterol 1996;31:154–159.

Tables

Table 1: Baseline characteristics of study population. Numbers (percentage) are reported in the table.

	All N = 8267 (100)		The PREDICT-NBS cohort N = 7527 (91.0)		The NorDIBD cohort N = 740 (9.0)	
	CD	**UC**	**CD**	**UC**	**CD**	**UC**
N	3732 (45.1)	4535 (54.9)	3354 (44.6)	4173 (55.4)	378 (51.1)	362 (48.9)
Sex						
Female	2081 (55.8)	2420 (53.4)	1882 (56.1)	2221 (53.2)	199 (52.6)	199 (55.0)
Male	1651 (44.2)	2115 (46.6)	1472 (43.9)	1952 (46.8)	179 (47.4)	163 (45.0)
Age at diagnosis						
<17 years	823 (22.1)	774 (17.1)	784 (23.4)	756 (18.1)	39 (10.3)	18 (5.0)
17-40 years	2822 (75.6)	3615 (79.7)	2570 (76.6)	3417 (81.9)	252 (66.7)	198 (54.7)
≥40 years	87 (2.3)	146 (3.2)	-	-	87 (23.0)	146 (40.3)
Calendar year at diagnosis						
1996-2005	534 (14.3)	579 (12.8)	434 (12.9)	491 (11.8)	101 (26.7)	88 (24.3)
2005-2015	1943 (52.1)	2474 (54.6)	1790 (53.4)	2312 (55.4)	153 (40.5)	162 (44.8)
2015-2020	1254 (33.6)	1482 (32.7)	1130 (33.7)	1370 (32.8)	124 (32.8)	112 (30.9)

CD: Crohn's disease, UC: ulcerative colitis, PREDICT-NBS: PREDICT neonatal blood spots, NorDIBD: North Denmark inflammatory bowel disease

Figure legends



Figure 1: Association between susceptibility PGS and laboratory biochemical test results at different time points. Plot showing β estimates and their 95% CI for association between laboratory test results (CRP, f-calpro, and hemoglobin) and SD standardized susceptibility PGS for CD and UC separately. For each individual, the test results were calculated as following: Diagnosis = test result closest to date of diagnosis (±six months), and post-diagnosis = the median value of all tests in the time intervals (0.5,1.5), [1.5, 2.5), [2.5,3.5), [3.5,4.5), and [4.5,5.5) years after diagnosis. Estimates and 95% CIs are showed. *P*-values were

435 adjusted for multiple testing using the Bonferroni correction for six tests. The dots are shaped based on
436 significance after adjusting for multiple testing. Dot sizes are based on number of individuals with available
437 test results in that given period.

438 CD: Crohn's disease, UC: ulcerative colitis, PGS: polygenic score, SD: standard deviation, CRP: C-reactive
439 protein, f-calpro: fecal calprotectin, CI: confidence interval, NS: not significant

440


A)
PGS quintile Q1 Q2 Q3 Q4
Cumulative incidence of hospitalization
0.0 0.2 0.4 0.6
0 500 1000 1500 2000 2500 3000
Days since diagnosis
No. at risk
Q1 747 503 473 436 367 303 240
Q2 746 445 418 380 303 243 194
Q3 746 440 403 367 297 228 170
Q4 746 445 409 360 289 220 172
Q5 747 387 337 294 235 189 134
B)
PGS quintile Q1 Q2 Q3 Q4
Cumulative incidence of major surgery
0.0 0.1 0.2 0.3 0.4
0 500 1000 1500 2000 2500 3000
Days since diagnosis
No. at risk
Q1 747 700 686 649 553 467 384
Q2 746 660 636 591 500 425 348
Q3 746 658 628 590 498 404 324
Q4 746 643 606 549 462 371 304
Q5 747 635 594 551 471 403 321
C)
PGS quintile Q1 Q2 Q3 Q4
Cumulative incidence of hospitalization
0.0 0.2 0.4 0.6
0 500 1000 1500 2000 2500 3000
Days since diagnosis
No. at risk
Q1 907 667 644 601 519 442 375
Q2 907 655 614 567 465 411 345
Q3 907 628 584 547 466 362 291
Q4 907 596 554 496 411 345 279
Q5 907 543 504 462 389 332 265
D)
PGS quintile Q1 Q2 Q3 Q4
Cumulative incidence of major surgery
0.0 0.1 0.2 0.3 0.4
0 500 1000 1500 2000 2500 3000
Days since diagnosis
No. at risk
Q1 907 870 855 809 718 616 535
Q2 907 865 845 804 692 608 513
Q3 907 848 830 796 700 575 478
Q4 907 852 827 776 661 568 471
Q5 907 826 801 763 663 577 488

441

442 **Figure 2: Time to severity event split by PGS quintiles. A)** Cumulative incidence of IBD-related
443 hospitalization split by CD susceptibility PGS quintiles within the CD cohort. **B)** Cumulative incidence of IBD-
444 related major surgery split by CD susceptibility PGS quintiles within the CD cohort. **C)** Cumulative incidence
445 of IBD-related hospitalization split by UC susceptibility PGS quintiles within the UC cohort. **D)** Cumulative
446 incidence of IBD-related major surgery split by UC susceptibility PGS quintiles within the UC cohort.

447 UC: ulcerative colitis, CD: Crohn's disease, PGS: polygenic score, Q1-Q5: Quintiles 1 to 5, where Q1 has the
448 lowest quintile of PGS scores, and Q5 the highest.

449



Figure 3: Susceptibility PGS related to IBD severity. A) Violin plot of PGS values of CD susceptibility (normalized to SDs from the mean) for controls and CD severity groups. **B)** Violin plot of PGS values of UC susceptibility (normalized to SDs from the mean) for controls and UC severity groups. **C)** Forest plot of the estimated association between the PGS of susceptibility for developing CD and UC and the different entities making up the combined severity definition. All summary statistics are outputted from logistic regressions. *P*-values were adjusted for multiple testing using the Bonferroni correction for ten tests.

457 CD: Crohn's disease, UC: ulcerative colitis, OR: odds ratio, PGS: polygenic score, SD: standard deviation, CI:
458 confidence interval

459


A)
B)
C)
D)
E)
F)
Proportion
Quintile
Biologic therapies
Immuno-modulators
Treatments with corticosteroids
G)
Disease
N
OR per SD [95% CI]
P adjusted
Required biologic therapies
CD
1438 vs. 1914
1.35 [1.25—1.45]
3.01×10^-14
UC
908 vs. 3241
1.31 [1.21—1.42]
2.28×10^-10
Required immunomodulators
CD
2081 vs. 1271
1.47 [1.36—1.58]
1.76×10^-22
UC
1292 vs. 2857
1.29 [1.20—1.38]
5.39×10^-12
OR per SD [95% CI]

460

461 **Figure 4: Susceptibility PGS related to treatment use.** Per quintile of susceptibility PGS, we generated the
462 number of different biologic therapies used in the first three years after diagnosed based on the proportion
463 of patients with CD (**A**) and UC (**B**). Similarly, we generated the number of different immunomodulators
464 used in the first three years after diagnosed based on the proportion of patients with CD (**C**) and UC (**D**).
465 Lastly, we calculated the total number of treatments with systemic corticosteroids (one treatment is defined
466 as 1500 mg prednisolone equivalent dose) that patients received in the three years after diagnosis based on
467 their PGS quintile for patients with CD (**E**) and UC (**F**).

468 CD: Crohn's disease, UC: ulcerative colitis, PGS: polygenic score, OR: odds ratio, SD: standard deviation, CI:
469 confidence interval

470



471

472 **Figure 5: Results of sensitivity analyses adjusting for disease location and extent.** We inferred disease
473 location (CD) and extend (UC) from the registries and adjusted for them as sensitivity analyses of the
474 association between susceptibility PGS and disease outcomes. **A**) The estimated HR for time to
475 hospitalization and major surgery, also adjusting for disease location and extend. **B**) All binary disease
476 outcomes were likewise adjusted for disease location and extend.

477 CD: Crohn's disease, UC: ulcerative colitis, PGS: polygenic score, OR: odds ratio, SD: standard deviation, CI:
478 confidence interval, HR; hazard ratio